Thermo Fisher Scientific Inc. $TMO Shares Purchased by Canvas Wealth Advisors LLC

Canvas Wealth Advisors LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 170.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,394 shares of the medical research company’s stock after acquiring an additional 878 shares during the quarter. Canvas Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $565,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of TMO. Brighton Jones LLC boosted its holdings in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. PFG Investments LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.0% in the 1st quarter. PFG Investments LLC now owns 2,222 shares of the medical research company’s stock worth $1,106,000 after purchasing an additional 86 shares during the last quarter. Finally, Intact Investment Management Inc. boosted its position in Thermo Fisher Scientific by 19.2% during the 1st quarter. Intact Investment Management Inc. now owns 3,100 shares of the medical research company’s stock valued at $1,543,000 after purchasing an additional 500 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 0.4%

Shares of TMO opened at $539.05 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The stock has a market capitalization of $203.55 billion, a P/E ratio of 31.18, a P/E/G ratio of 2.93 and a beta of 0.77. The business’s 50-day moving average price is $495.74 and its 200 day moving average price is $448.98.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 earnings per share. The firm’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last three months. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the topic of a number of analyst reports. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Barclays boosted their target price on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Finally, Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $589.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.